NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) can significantly delay the onset of acute exacerbation of COPD

Compared with the control group, tiotropium bromide(136310-93-5) can significantly delay the occurrence of acute exacerbation of COPD, COPD acute exacerbation of the risk of 17% Chronic obstructive pulmonary disease (COPD) is currently the world's fourth-leading cause of death and is expected to rise to the third largest cause of death in the next decade. Recently, the "New England Journal of Medicine" published "tiotropium bromide(136310-93-5) to prevent acute exacerbation of COPD" study (POET-COPD study) results. The study confirmed that tiotropium bromide in reducing the risk of acute exacerbation of COPD is better than the control group. The POET-COPD study was a one-year randomized, double-blind, double-simulated, parallel-group study of 7376 moderate and severe COPD patients in 725 centers in 25 countries. The study included at least 40 years of age, with a history of smoking of at least 10 packs per year, was clearly diagnosed as moderate to severe COPD, and at least once in the previous year, systemic corticosteroids and /or antibiotics and /or acute exacerbations of hospitalization. The aim of this study was to compare the effects of long-acting bronchodilator tiotropium and salmeterol on acute exacerbation of COPD.

The results show that tiotropium can significantly delay the onset of acute exacerbation of COPD for the first time and reduce the risk of acute exacerbation by 17% (p <0.0001) compared with the control drug.

Compared with the control group, the risk of moderate acute exacerbation in the tiotropium bromide(136310-93-5) treatment group decreased by 14% (p <0.001), while the risk of severe acute exacerbation of hospitalization decreased by 28% (p <0.001 ).


Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved